Aardvark Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
Aardvark Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) has a cash flow conversion efficiency ratio of -0.151x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.52 Million) by net assets ($122.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Cash flow conversion efficiency of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AARD stock price and chart for real-time trading data and today's change.
Aardvark Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Aardvark Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aardvark Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aardvark Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see AARD company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PUC Bhd
KLSE:0007
|
-0.088x |
|
MST GOLF GROUP BERHAD
KLSE:5316
|
0.045x |
|
Advance NanoTek Limited
F:BBJ
|
0.047x |
|
Cuhadaroglu Metal Sanayi ve Pazarlama AS
IS:CUSAN
|
0.946x |
|
CVD Equipment Corporation
NASDAQ:CVV
|
0.016x |
|
Samil Enterprise Co. Ltd
KQ:002290
|
0.033x |
|
Wysiwyg Studios Co. Ltd
KQ:299900
|
-0.014x |
|
Capital Partners S.A.
WAR:CPA
|
-0.505x |
Annual Cash Flow Conversion Efficiency for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. Review AARD free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-54.64 Million | $-18.09 Million | 0.331x | +97.79% |
| 2023-12-31 | $-34.80 Million | $-5.82 Million | 0.167x | -55.68% |
| 2022-12-31 | $-27.92 Million | $-10.54 Million | 0.378x | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more